Schedule 13G ownership disclosure
Lomond Therapeutics Holdings, Inc.
Common Stock · CUSIP: 54173L101
Event date: 2025-01-24
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Yosemite Fund I, L.P.
Shares: 2,500,000.00 · Class: 8.4%
- Yosemite GP I, L.L.C.
Shares: 2,500,000.00 · Class: 8.4%
- Reed Jobs
Shares: 2,500,000.00 · Class: 8.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-002468
- Form type
- SCHEDULE 13G
- Filer
- Lomond Therapeutics Holdings, Inc.
- CIK
- CIK 1900520
- Filed
- Jan 31, 2025
- Reporting period
- Jan 24, 2025
- Description
- Schedule 13G beneficial ownership